Elanix Biotechnologies AG (DB:ELN) announced that it has signed a term sheet for a financing facility with a leading institutional investor for gross proceeds of up to €11,000,000 on February 14, 2018. The transaction will involve participation from a United States based fund. The facility will be availed over a period of three years.